These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11074537)

  • 1. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
    Okugawa Y; Wada H; Noda T; Sakakura M; Nakasaki T; Watanabe R; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Nobori T; Shiku H
    Am J Hematol; 2000 Nov; 65(3):210-4. PubMed ID: 11074537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex.
    Iversen N; Strekerud FG; Abildgaard U
    Blood Coagul Fibrinolysis; 2000 Oct; 11(7):591-8. PubMed ID: 11085278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor.
    Takahashi H; Sato N; Shibata A
    Thromb Res; 1995 Nov; 80(4):339-48. PubMed ID: 8585047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Nakasaki T; Hiyoyama K; Mori Y; Nishikawa M; Deguchi H; Deguchi K; Gabazza EC; Shiku H
    Am J Hematol; 1999 Feb; 60(2):94-8. PubMed ID: 9929099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
    Am J Hematol; 1997 Aug; 55(4):169-74. PubMed ID: 9257875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases.
    Asakura H; Ontachi Y; Mizutani T; Kato M; Saito M; Morishita E; Yamazaki M; Suga Y; Takami A; Miyamoto K; Nakao S
    Blood Coagul Fibrinolysis; 2001 Jan; 12(1):1-8. PubMed ID: 11229821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
    Wada H; Sakuragawa N; Mori Y; Takagi M; Nakasaki T; Shimura M; Hiyoyama K; Nisikawa M; Gabazza EC; Deguchi K; Kazama M; Shiku H
    Am J Hematol; 1999 Apr; 60(4):273-8. PubMed ID: 10203100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation.
    Yamamuro M; Wada H; Kumeda K; Inoue A; Tsuji I; Nakasaki T; Shimura M; Hiyoyama K; Gabazza EC; Nishikawa M; Deguchi K; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):491-7. PubMed ID: 9818999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation.
    Watanabe R; Wada H; Yamamuro M; Inoue A; Watanabe M; Kumeda K; Sakakura M; Okugawa Y; Nakasaki T; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Nobori T; Shiku H
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):71-7. PubMed ID: 12643327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers.
    Wada H; Gabazza E; Nakasaki T; Shimura M; Hiyoyama K; Deguchi K; Nishikawa M; Sakuragawa N; Shiku H
    Semin Thromb Hemost; 2000; 26(1):17-21. PubMed ID: 10805276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients.
    Wada H; Sakuragawa N; Shiku H
    Semin Thromb Hemost; 1998; 24(3):293-7. PubMed ID: 9701463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy.
    Mosad E; Elsayh KI; Eltayeb AA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):80-7. PubMed ID: 19689998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation.
    Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Deguchi H; Mori Y; Kaneko T; Deguchi K; Fujii J; Shiku H
    Am J Hematol; 1996 Apr; 51(4):255-60. PubMed ID: 8602623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.
    Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Mori Y; Deguchi K; Shiku H
    Pol J Pharmacol; 1996; 48(2):225-8. PubMed ID: 9112656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
    Watanabe R; Wada H; Sakakura M; Mori Y; Nakasaki T; Okugawa Y; Gabazza EC; Hayashi T; Nishioka J; Suzuki K; Shiku H; Nobori T
    Am J Hematol; 2000 Sep; 65(1):35-40. PubMed ID: 10936861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
    Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
    Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.
    Bregengård C; Nordfang O; Wildgoose P; Svendsen O; Hedner U; Diness V
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):699-706. PubMed ID: 8292719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
    Seo JW; Kim HK; Kim JE; Park S; Cho HI
    Thromb Res; 2009 Feb; 123(4):565-72. PubMed ID: 18479738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.